CLINICAL TRIALS PROFILE FOR JEMPERLI
✉ Email this page to a colleague
All Clinical Trials for JEMPERLI
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04926324 ↗ | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Not yet recruiting | GlaxoSmithKline | Phase 1/Phase 2 | 2021-12-31 | This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures. |
NCT04926324 ↗ | A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers | Not yet recruiting | Joseph Caster, Ph.D., M.D. | Phase 1/Phase 2 | 2021-12-31 | This clinical trial is designed to determine the maximum tolerated dose of niraparib when combined with dostarlimab and hypofractionated radiation for locally advanced rectal cancer. Once this is determined, this dose will be tested to identify what impact it has on the tumor as well as patient reported outcome measures. |
NCT05526989 ↗ | Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Not yet recruiting | GlaxoSmithKline | Phase 2 | 2022-09-15 | The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for JEMPERLI
Condition Name
Clinical Trial Locations for JEMPERLI
Trials by Country
Clinical Trial Progress for JEMPERLI
Clinical Trial Phase
Clinical Trial Sponsors for JEMPERLI
Sponsor Name